Spanish Red Biotech Pipeline

MSD

Pembrolizumab/Lenvatinib

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma
Phase: 3Phase III in Spain, 2Phase II in Spain, 1Phase I